SCHEMBL4160374

SCHEMBL4160374

CCOc1[c]c(C(N)=O)ncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.42
TSHR P16473 1/20 0.40
IKBKB O14920 2/20 0.40
BPTF Q12830 1/20 0.37
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3355639 0.83 KDM4E (0.39) PARP10IKBKBBPTFMKNK1MKNK2
SCHEMBL3232701 0.73 SIRT3 (0.36) TSHRMKNK1MKNK2KMT2AL3MBTL1
SCHEMBL4169428 0.72 KMT2A (0.36) PARP10IKBKBALDH1A1MKNK1MKNK2
SCHEMBL1551487 0.71 MKNK1 (0.41) TSHRIKBKBMKNK1MKNK2L3MBTL1
SCHEMBL2586506 0.69 CDK8 (0.38) LMNAMKNK1MKNK2L3MBTL1
SCHEMBL8107309 0.69 HPGD (0.39) TSHRMAPK1ALDH1A1KMT2AL3MBTL1
SCHEMBL14353433 0.69 KDM4E (0.37) ALDH1A1HTTMKNK1MKNK2L3MBTL1
SCHEMBL2265945 0.68 HPGD (0.34) ALDH1A1LMNAKMT2AMEN1MAPT
SCHEMBL8924864 0.67 LMNA (0.37) MAPK1ALDH1A1LMNANPSR1CA12
SCHEMBL7456442 0.67 MAPK9 (0.36) ALDH1A1HTTMKNK1MKNK2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 PARP10 2411/4885TSHR 4300/4885IKBKB 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.